Literature DB >> 34013329

Reconciling multiple connectivity scores for drug repurposing.

Kewalin Samart1, Phoebe Tuyishime2, Arjun Krishnan3, Janani Ravi4.   

Abstract

The basis of several recent methods for drug repurposing is the key principle that an efficacious drug will reverse the disease molecular 'signature' with minimal side effects. This principle was defined and popularized by the influential 'connectivity map' study in 2006 regarding reversal relationships between disease- and drug-induced gene expression profiles, quantified by a disease-drug 'connectivity score.' Over the past 15 years, several studies have proposed variations in calculating connectivity scores toward improving accuracy and robustness in light of massive growth in reference drug profiles. However, these variations have been formulated inconsistently using various notations and terminologies even though they are based on a common set of conceptual and statistical ideas. Therefore, we present a systematic reconciliation of multiple disease-drug similarity metrics ($ES$, $css$, $Sum$, $Cosine$, $XSum$, $XCor$, $XSpe$, $XCos$, $EWCos$) and connectivity scores ($CS$, $RGES$, $NCS$, $WCS$, $Tau$, $CSS$, $EMUDRA$) by defining them using consistent notation and terminology. In addition to providing clarity and deeper insights, this coherent definition of connectivity scores and their relationships provides a unified scheme that newer methods can adopt, enabling the computational drug-development community to compare and investigate different approaches easily. To facilitate the continuous and transparent integration of newer methods, this article will be available as a live document (https://jravilab.github.io/connectivity_scores) coupled with a GitHub repository (https://github.com/jravilab/connectivity_scores) that any researcher can build on and push changes to.
© The Author(s) 2021. Published by Oxford University Press.

Entities:  

Keywords:  CMap and LINCS L1000; connectivity mapping; disease gene signature; drug repositioning/repurposing; similarity metrics; transcriptomics

Mesh:

Substances:

Year:  2021        PMID: 34013329      PMCID: PMC8597919          DOI: 10.1093/bib/bbab161

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  40 in total

1.  Evaluation of analytical methods for connectivity map data.

Authors:  Jie Cheng; Qing Xie; Vinod Kumar; Mark Hurle; Johannes M Freudenberg; Lun Yang; Pankaj Agarwal
Journal:  Pac Symp Biocomput       Date:  2013

2.  A flexible, interpretable, and accurate approach for imputing the expression of unmeasured genes.

Authors:  Christopher A Mancuso; Jacob L Canfield; Deepak Singla; Arjun Krishnan
Journal:  Nucleic Acids Res       Date:  2020-12-02       Impact factor: 16.971

3.  A comprehensive evaluation of connectivity methods for L1000 data.

Authors:  Kequan Lin; Lu Li; Yifei Dai; Huili Wang; Shuaishuai Teng; Xilinqiqige Bao; Zhi John Lu; Dong Wang
Journal:  Brief Bioinform       Date:  2020-12-01       Impact factor: 11.622

4.  Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease.

Authors:  Joel T Dudley; Marina Sirota; Mohan Shenoy; Reetesh K Pai; Silke Roedder; Annie P Chiang; Alex A Morgan; Minnie M Sarwal; Pankaj Jay Pasricha; Atul J Butte
Journal:  Sci Transl Med       Date:  2011-08-17       Impact factor: 17.956

5.  DMAP: a connectivity map database to enable identification of novel drug repositioning candidates.

Authors:  Hui Huang; Thanh Nguyen; Sara Ibrahim; Sandeep Shantharam; Zongliang Yue; Jake Y Chen
Journal:  BMC Bioinformatics       Date:  2015-09-25       Impact factor: 3.169

6.  Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets.

Authors:  Bin Chen; Li Ma; Hyojung Paik; Marina Sirota; Wei Wei; Mei-Sze Chua; Samuel So; Atul J Butte
Journal:  Nat Commun       Date:  2017-07-12       Impact factor: 14.919

7.  Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery.

Authors:  Chen-Tsung Huang; Chiao-Hui Hsieh; Yun-Hsien Chung; Yen-Jen Oyang; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  iScience       Date:  2019-05-04

8.  ChEMBL: towards direct deposition of bioassay data.

Authors:  David Mendez; Anna Gaulton; A Patrícia Bento; Jon Chambers; Marleen De Veij; Eloy Félix; María Paula Magariños; Juan F Mosquera; Prudence Mutowo; Michal Nowotka; María Gordillo-Marañón; Fiona Hunter; Laura Junco; Grace Mugumbate; Milagros Rodriguez-Lopez; Francis Atkinson; Nicolas Bosc; Chris J Radoux; Aldo Segura-Cabrera; Anne Hersey; Andrew R Leach
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

9.  Exploration of databases and methods supporting drug repurposing: a comprehensive survey.

Authors:  Ziaurrehman Tanoli; Umair Seemab; Andreas Scherer; Krister Wennerberg; Jing Tang; Markus Vähä-Koskela
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

10.  signatureSearch: environment for gene expression signature searching and functional interpretation.

Authors:  Yuzhu Duan; Daniel S Evans; Richard A Miller; Nicholas J Schork; Steven R Cummings; Thomas Girke
Journal:  Nucleic Acids Res       Date:  2020-12-02       Impact factor: 16.971

View more
  3 in total

1.  DREAM: a database of experimentally supported protein-coding RNAs and drug associations in human cancer.

Authors:  Shupeng Li; Lulu Li; Xiangqi Meng; Penggang Sun; Yi Liu; Yuntang Song; Sijia Zhang; Chuanlu Jiang; Jinquan Cai; Zheng Zhao
Journal:  Mol Cancer       Date:  2021-11-13       Impact factor: 27.401

2.  Causal reasoning over knowledge graphs leveraging drug-perturbed and disease-specific transcriptomic signatures for drug discovery.

Authors:  Daniel Domingo-Fernández; Yojana Gadiya; Abhishek Patel; Sarah Mubeen; Daniel Rivas-Barragan; Chris W Diana; Biswapriya B Misra; David Healey; Joe Rokicki; Viswa Colluru
Journal:  PLoS Comput Biol       Date:  2022-02-25       Impact factor: 4.475

3.  Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic Cancer.

Authors:  Chin-King Looi; Li-Lian Gan; Wynne Sim; Ling-Wei Hii; Felicia Fei-Lei Chung; Chee-Onn Leong; Wei-Meng Lim; Chun-Wai Mai
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.